AbbVie: Venclexta Combination Study Didn't Meet Primary Endpoint
February 28 2020 - 8:05PM
Dow Jones News
By Josh Beckerman
AbbVie Inc. said a clinical trial of its Venclexta (venetoclax)
drug in combination with low-dose cytarabine didn't meet its
primary endpoint of statistically significant improvement of
overall survival for patients with acute myeloid leukemia.
Venclexta is being developed by AbbVie and Roche Holding AG.
AbbVie said results from the VIALE-C trial "are indicative of
clinical activity" for the combination. The company said the
VIALE-A trial evaluating the drug in combination with azacytidine
is ongoing.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
February 28, 2020 19:50 ET (00:50 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
